CAJ | 학술논문

目的：探讨肝动脉化疗栓塞（TACE）治疗巴塞罗那临床肝癌分期（BCLC） B期肝细胞肝癌（HCC）的预后及生存率。方法对2007年2月-2013年1月行TACE治疗的BCLC B期HCC患者总共有197例进行回顾性分析，且所有病例通过住院及电话随访，根据患者临床资料进行预后及生存分析。结果197例HCC患者中位随访时间为12（6～77）个月。中位生存期为24（2～77）个月。肝功能Child-Pugh A级患者生存率明显优于Child-Pugh B级患者（各为35个月和15个月，P<0.01）。 BCLC B1期患者生存率明显优于B2，B3和B4，中位生存期分别为35、25、9和7个月（P <0.01）。不同年龄、性别、民族、肝炎病史以及甲胎蛋白水平之间无明显生存差异。结论 TACE治疗BCLC B期HCC患者可以明显提高其生存率，并且通过BCLC分期及肝功能Child-Pugh分级可以预测和评估患者TACE术后的预后及生存率。
목적：탐토간동맥화료전새（TACE）치료파새라나림상간암분기（BCLC） B기간세포간암（HCC）적예후급생존솔。방법대2007년2월-2013년1월행TACE치료적BCLC B기HCC환자총공유197례진행회고성분석，차소유병례통과주원급전화수방，근거환자림상자료진행예후급생존분석。결과197례HCC환자중위수방시간위12（6～77）개월。중위생존기위24（2～77）개월。간공능Child-Pugh A급환자생존솔명현우우Child-Pugh B급환자（각위35개월화15개월，P<0.01）。 BCLC B1기환자생존솔명현우우B2，B3화B4，중위생존기분별위35、25、9화7개월（P <0.01）。불동년령、성별、민족、간염병사이급갑태단백수평지간무명현생존차이。결론 TACE치료BCLC B기HCC환자가이명현제고기생존솔，병차통과BCLC분기급간공능Child-Pugh분급가이예측화평고환자TACE술후적예후급생존솔。
Objective To investigate the prognosis and survival rate of the patients with Barcelona clinic liver cancer stage B hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) treatment. Methods During the period from Feb. 2007 to Jan. 2013 at authors’ hospital, a total of 197 patients with Barcelona clinic liver cancer stage B HCC were treated with TACE. The clinical data were retrospectively analyzed. All patients were followed up from Feb. 2007 to July 2013 by admission to hospital of by phone. Based on the clinical materials the prognosis and survival rate were analyzed. Results The median follow-up time was 12 (6- 77) months and the median survival time was 24 (2 - 77) months. The survival rate of patients with liver function of Child-Pugh class A was significantly higher than that of patients with liver function of Child-Pugh class B (35 months vs. 15 months, P< 0.01). The survival rate of patients with Barcelona stage B1 was significantly better than those of patients with Barcelona stage B2, B3 and B4, and the median survival time of patients with Barcelona stage B1, B2, B3 and B4 was 35, 25, 9 and 7 months respectively (P < 0.01). No significant differences in survival rate existed between patients with different age, sex, nation, history of hepatitis and AFP levels. Conclusion TACE treatment can significantly increase the survival rate of patients with Barcelona stage B hepatocellular carcinoma. Barcelona staging and Child-Pugh classification can predict the prognosis and survival rate of patients with HCC after TACE.